Skip to main content

In Situ Hybridization Market Growth Analysis - Global Forecast To 2021

According to the new market research report "In situ Hybridization Market by Technique (FISH, CISH), Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic And Research Institutions) - Global Forecast to 2021", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities.
In the coming years, the market is expected to witness the highest growth in the Asia-Pacific region. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.
North America is expected to account for the largest share of the global market. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents.
Browse and in-depth TOC on " In situ Hybridization Market "
60– Tables
26 – Figures
194 - Pages
In the U.S., the in situ hybridization market is driven by increasing government initiatives, growing biomedical research, rising prevalence of cancer, and growing demand for companion diagnostics and personalized medicine.  In Canada, the growth of the market is driven by increased government funding and growing prevalence of cancer.
On the basis of technique, the global market is segmented into fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). The FISH segment is expected to command the largest share of the global in situ hybridization market, by technique in 2016. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to factors such as like high resolution of this technique, rising adoption in research activities & laboratories to diagnose cancer, chromosomal abnormalities, and infectious diseases, among others.
The in situ hybridization market is projected to reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, at a CAGR of 5.8% in the next five years (2016 to 2021). Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.
The global market is segmented on the basis of technique, application, and end user. By technique, the market is categorized into fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). The FISH segment is expected to command the largest share of the global market, by technique in 2016. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to factors such as like high resolution of this technique, rising adoption in research activities & laboratories to diagnose cancer, chromosomal abnormalities, and infectious diseases, among others.
Key Players:
Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.) are some of the key players in the in situ hybridization market worldwide.
 
Click for Adjacent Markets Report Available.
Request for bundle reports: 
https://www.marketsandmarkets.com/RequestBundleReport.asp?id=212028829

Comments

Post a Comment

Popular posts from this blog

Top 10 Medical Device Technologies Which Booming in 2019

The global top 10 medical device technologies market is expected to reach USD 428.97 Billion by 2020, at a CAGR of 5.5% from 2015 to 2020. Growth in the global top 10 medical device technologies market is mainly driven by factors such as the rising prevalence of chronic diseases and related increase in disability-adjusted life years (DALYs), technological advancements in medical devices, and growing aging population. Moreover, increasing investments from government bodies and private players in healthcare sectors in emerging economies and increasing focus of key players on emerging countries are creating new growth opportunities for this market. However, uncertainty in reimbursement and excise tax on medical devices in the U.S. are restraining the growth of the market. The top 10 medical device technologies market studied in this report is mainly segmented by types and region. Based on type, the top 10 medical device technologies market is segmented into in vitro diagnostics (IV

Interventional Oncology Market Latest Trends 2019

The interventional oncology market is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in 2019. The market is expected to grow at a CAGR of 6.8% from 2019 to 2024. The growth of this market is primarily driven by the rising preference for minimally invasive procedures, expansion of the target patient population, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and the increasing government investments and funding for interventional oncology and related cancer research. The introduction of advanced interventional oncology products is a major technological advancement in the interventional oncology field. These advancements are largely related to the commercialization of more effective, simple, and easy-to-use products for interventional oncology procedures. Based on product, the interventional oncology market is segmented into ablation devices, embolization devices, an